M&T Bank Corp acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,954 shares of the specialty pharmaceutical company’s stock, valued at approximately $213,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares during the last quarter. Northern Trust Corp increased its stake in shares of Supernus Pharmaceuticals by 2.8% during the 2nd quarter. Northern Trust Corp now owns 653,262 shares of the specialty pharmaceutical company’s stock worth $28,155,000 after purchasing an additional 17,836 shares during the last quarter. D.A. Davidson & CO. boosted its holdings in shares of Supernus Pharmaceuticals by 10.7% during the 2nd quarter. D.A. Davidson & CO. now owns 14,596 shares of the specialty pharmaceutical company’s stock worth $629,000 after buying an additional 1,414 shares during the period. Citigroup Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 111.6% during the 2nd quarter. Citigroup Inc. now owns 150,176 shares of the specialty pharmaceutical company’s stock worth $6,473,000 after buying an additional 79,203 shares during the period. Finally, Pinebridge Investments L.P. boosted its holdings in shares of Supernus Pharmaceuticals by 1.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after buying an additional 86 shares during the period. Institutional investors own 95.36% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “M&T Bank Corp Takes $213,000 Position in Supernus Pharmaceuticals, Inc. (SUPN)” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/mt-bank-corp-takes-213000-position-in-supernus-pharmaceuticals-inc-supn/1634114.html.

In other news, VP Padmanabh P. Bhatt sold 3,709 shares of Supernus Pharmaceuticals stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the completion of the transaction, the vice president now owns 17,500 shares in the company, valued at $791,525. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $49.86, for a total transaction of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares of the company’s stock, valued at approximately $623,250. The disclosure for this sale can be found here. Insiders sold 153,709 shares of company stock valued at $7,223,108 in the last quarter. Corporate insiders own 6.70% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 41.35 on Monday. Supernus Pharmaceuticals, Inc. has a one year low of $17.25 and a one year high of $50.04. The company’s 50 day moving average is $43.22 and its 200 day moving average is $39.46. The company has a market cap of $2.10 billion, a P/E ratio of 20.86 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

Several analysts recently commented on the stock. Cantor Fitzgerald lifted their target price on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, July 5th. Stifel Nicolaus downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 target price for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Cowen and Company reaffirmed a “positive” rating and set a $50.00 target price (up previously from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $45.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, September 8th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $47.71.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.